Hu S L, Hellström I, Hellström K E
Biotechnology. 1992;20:327-43. doi: 10.1016/b978-0-7506-9265-6.50020-8.
Immunization with anti-idiotypic antibodies can induce cell-mediated and humoral antitumor immunity in animal models. This immunity can sometimes cause tumor destruction. However, more needs to be learned about how best to induce the type of immune response that is responsible for tumor destruction, since the presence of anti-idiotypic antibodies has been shown occasionally to enhance, rather than to inhibit, tumor growth. There is evidence suggesting that immunization of human cancer patients with Ab2 can have therapeutic benefit, and also that patients who mount a vigorous Ab2 response following treatment with an Ab1 may do clinically better than those who do not make any Ab2. Although the generation of Ab2 related to infused antitumor Ab1 does not cause tumor rejection in the majority of patients, and although the clinical data from patients given Ab2 are scarce, the suggestion that Ab2 may cause destruction of human cancers indicates that further work in this area may become rewarding.
在动物模型中，用抗独特型抗体进行免疫可诱导细胞介导的和体液性抗肿瘤免疫。这种免疫有时可导致肿瘤破坏。然而，关于如何最好地诱导负责肿瘤破坏的免疫反应类型，仍有更多需要了解的地方，因为已表明抗独特型抗体的存在偶尔会增强而非抑制肿瘤生长。有证据表明，用Ab2对人类癌症患者进行免疫可能具有治疗益处，而且在用Ab1治疗后产生强烈Ab2反应的患者在临床上可能比未产生任何Ab2的患者表现更好。尽管与注入的抗肿瘤Ab1相关的Ab2的产生在大多数患者中不会导致肿瘤排斥，并且尽管给予Ab2的患者的临床数据很少，但Ab2可能导致人类癌症破坏的这一暗示表明，该领域的进一步研究可能会有所收获。
